KatherineHannaTkaczukMD

Breast Cancer, Hematologic Oncology

Professor of Medicine, University Maryland School of Medicine; Director, Breast Evaluation and Treatment Program, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center

Request Appointment

Overview of Dr. Tkaczuk

Dr. Katherine Tkaczuk is an oncologist in Baltimore, MD and is affiliated with multiple hospitals in the area, including University of Maryland Medical Center, University of Maryland Baltimore Washington Medical Center, and Veterans Affairs Maryland Health Care System-Baltimore Division. She received her medical degree from Wroclaw Medical University and has been in practice 33 years. Dr. Tkaczuk accepts several types of health insurance, listed below. She is one of 30 doctors at University of Maryland Baltimore Washington Medical Center and one of 102 doctors at University of Maryland Medical Center who specialize in Oncology. She has more than 80 publications and over 500 citings.

Office
22 S Greene St
Baltimore, MD 21201
Book by Phone+1(443) 348-0745

Fax+1 410-328-6896

Education & Training

University of MarylandFellowship, Hematology and Medical Oncology, 1989 - 1992
St Agnes HealthCareResidency, Internal Medicine, 1986 - 1989
St Agnes HealthCareInternship, Internal Medicine, 1986 - 1987
Wroclaw Medical UniversityClass of 1984

Certifications & Licensure

MD State Medical License 1987 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Top Doctors:Baltimore Area Castle Connolly, 2012
Top Doctors:Washington-Baltimore Castle Connolly, 2012
Join now to see all

Clinical Trials

A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Start of enrollment: 2010 Aug 13
Completed
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
Completed
Phase 2
1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over. Start of enrollment: 2014 Jan 01
Terminated
Phase 2
1380GCC: Prospective Study of GP-88 Blood Test in Healthy Women With Baseline Gail Model Risk Assessment Undergoing Screening for Breast Cancer Start of enrollment: 2014 Apr 01
Terminated
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Start of enrollment: 2017 Feb 02
Terminated
Phase 2
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery Start of enrollment: 2020 Feb 20
Recruiting
Phase 2
Roles: Contact, Principal Investigator
First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies Start of enrollment: 2022 Feb 14
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Identification of Functional Immune Biomarkers in Breast Cancer Patients.
Roshanak Derakhshandeh, Yuyi Zhu, Junxin Li, Danubia Hester, Rania Younis
International Journal of Molecular Sciences. 2024-11-16
Bazedoxifene as a Potential Cancer Therapeutic Agent Targeting IL-6/GP130 Signaling.
Changyou Shi, Taylor Bopp, Hui-Wen Lo, Katherine Tkaczuk, Jiayuh Lin
Current Oncology. 2024-09-25
A Prospective Trial of Single-Fraction Radiation to the Tumor Bed with a Novel Breast-Specific Stereotactic Radiation Therapy Device: The GammaPod.
Elizabeth M Nichols, Søren M Bentzen, Meghan Milburn, Susan B Kesmodel, Emily Bellavance
Advances in Radiation Oncology. 2024-04-01

Press Mentions

Post-ASCO News Alert: AstraZeneca’s/Merck’s Lynparza Use in Niche HR+ gBRCA-Mutant Breast Cancer Subgroup Could Compete with VerzenioJune 21st, 2021
Is There Medication to Prevent Breast Cancer?December 1st, 2023

Grant Support

Glycoprotein 88 Blood Test as Screening Test for Breast CancerMaryland Industry Partnership Grant2014–Present

Professional Memberships

American College of Physicians - ACP
Member
American Society of Clinical Oncology - ASCO
Member
American Medical Association - AMA
Member
American Association for Cancer Research - AACR
Member
American College of Physicians - ACP
Fellow
American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CareFirst BlueChoice Advantage
CareFirst BlueChoice Network POS
CareFirst BluePreferred PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
First Health PPO
Great West PPO
HealthAmerica HealthAssurance PPO
Humana ChoiceCare Network PPO
Medical Mutual of Ohio SuperMed Plus
Medical Mutual of Ohio SuperMed POS
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment